Enalapril
Brand: Vasotec (US/EU) / Enam (IN) / Enapril (BD)
Antihypertensive
ACE inhibitor (prodrug)
Pharmacokinetics
| Half-life | 11 hours |
| Tmax | 1 h |
| Bioavailability | 60 % (approx) |
| Protein Binding | 50 % |
| Volume of Distribution | 0.3 L/kg (approx) |
| Clearance Route | mixed |
| Active Metabolites | yes |
| Notes | Converted to enalaprilat; onset slower than ACE infusion agents; renal dose adjustment required. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Dry cough, hyperkalemia, dizziness, hypotension, rare angioedema
Contraindications:
Pregnancy, bilateral renal artery stenosis, prior ACE-inhibitor–induced angioedema
Precautions:
Monitor serum potassium and creatinine; reduce dose in renal impairment; avoid NSAIDs worsening renal function